切换至 "中华医学电子期刊资源库"

中华移植杂志(电子版) ›› 2020, Vol. 14 ›› Issue (03) : 188 -192. doi: 10.3877/cma.j.issn.1674-3903.2020.03.012

所属专题: 文献

荟萃分析

肾移植受者术后BK病毒激活危险因素的荟萃分析
张涛1, 周鑫1, 王彦峰1, 胡正斌1, 罗锐1, 叶啟发2,()   
  1. 1. 430071 武汉大学中南医院 武汉大学肝胆疾病研究院 移植医学技术湖北省重点实验室
    2. 430071 武汉大学中南医院 武汉大学肝胆疾病研究院 移植医学技术湖北省重点实验室;410013 长沙,中南大学湘雅三医院 卫生部移植医学工程技术研究中心
  • 收稿日期:2019-11-13 出版日期:2020-06-25
  • 通信作者: 叶啟发
  • 基金资助:
    医学腾飞计划——"转化医学、医学+医学平台建设项目"(临床医学)(TFLC2018003)

The related risk factors of BK virus activation in renal transplant recipients after transplantation: a meta-analysis

Tao Zhang1, Xin Zhou1, Yanfeng Wang1, Zhengbin Hu1, Rui Luo1, Qifa Ye2,()   

  1. 1. Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan 430071, China
    2. Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan 430071, China; The Third Xiangya Hospital of Central South University, Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Changsha 410013, China
  • Received:2019-11-13 Published:2020-06-25
  • Corresponding author: Qifa Ye
  • About author:
    Corresponding author: Ye Qifa, Email:
引用本文:

张涛, 周鑫, 王彦峰, 胡正斌, 罗锐, 叶啟发. 肾移植受者术后BK病毒激活危险因素的荟萃分析[J/OL]. 中华移植杂志(电子版), 2020, 14(03): 188-192.

Tao Zhang, Xin Zhou, Yanfeng Wang, Zhengbin Hu, Rui Luo, Qifa Ye. The related risk factors of BK virus activation in renal transplant recipients after transplantation: a meta-analysis[J/OL]. Chinese Journal of Transplantation(Electronic Edition), 2020, 14(03): 188-192.

目的

对国内外报道的肾移植术后BK病毒(BKV)激活的危险因素进行荟萃分析,为临床BKV肾病的防治提供参考。

方法

通过系统检索PubMed数据库、中国知网、万方数据库以及中国生物医学数据库从建库至2019年7月公开发表的关于肾移植术后BKV激活危险因素的相关研究论文,并通过其参考文献进行手工补充搜索。采用纽卡斯尔-渥太华量表对纳入文献进行质量评价,运用RevMan 5.3软件进行荟萃分析。

结果

最终纳入22篇文献,其中英文15篇、中文7篇。结果显示血液中检测到BKV的危险因素为排斥反应(OR=1.91,95%CI:1.30~2.80)、移植肾功能延迟恢复(OR=1.51,95%CI:0.99~2.31)、服用他克莫司(OR=1.50,95%CI:1.22~1.84)、使用抗胸腺细胞球蛋白(ATG)诱导(OR=1.75,95%CI:1.02~2.98)、使用输尿管支架(OR=1.98,95%CI:1.19~3.30)和合并CMV感染(OR=2.23,95%CI:1.61~3.09);而尿液中检测到BKV的危险因素为持续服用糖皮质激素(OR=1.49,95%CI:1.09~2.04)。

结论

肾移植术后服用他克莫司、合并CMV感染、使用输尿管支架和ATG诱导的受者发生BKV血症的风险更高,长期服用糖皮质激素的肾移植受者发生BKV尿症的风险更高。

Objective

To provide a meta-analysis of the risk factors of BKV activation after kidney transplantation basing on the related published reports and to provide reference for the prevention and treatment of BKV nephropathy.

Methods

The published papers related to BKV activation after kidney transplantation in the PubMed database, the Chinese journal full-text database, the Wanfang database, and the Chinese biomedical database from the establishment of the database to the July 2019 were systematically searched, and the references of the papers were manually searched for supplemental papers. The quality of each study was evaluated using the Newcastle-Ottawa scale. The data of the risk factors were extracted and meta-analysed by RevMan 5.3 statistical software.

Results

A total of 22 studies were included, 15 of which were English literatures and 7 were Chinese literatures. The results showed that the risk factors of BKV detected in the blood were rejection (OR=1.91, 95%CI: 1.30-2.80), delayed graft function (OR=1.51, 95%CI: 0.99-2.31), taking tacrolimus (OR=1.50, 95%CI: 1.22-1.84), using antithymocyte globulin(ATG) induction (OR: 1.75, 95%CI: 1.02-2.98), using ureteral stent (OR=1.98, 95%CI: 1.19-3.30) and those with CMV infection (OR=2.23, 95%CI: 1.61-3.09); the risk factor of BKV detected in the urine was continuous use of glucocorticoid (OR=1.49, 95%CI: 1.09-2.04).

Conclusions

Kidney transplant recipients taking tacrolimus, co-infection with CMV, using ureteral stent, and using ATG after kidney transplantation have a higher risk of BK viremia, and kidney transplant patients who have taken hormones for a long time have a higher risk of BK viruria.

图1 文献检索流程图
表1 纳入文献的基本特征
表2 肾移植受者术后BKV激活危险因素荟萃分析结果
危险因素 病毒检出部位 文章数量(篇) BKV阳性例数/总例数 异质性检验 OR 95%CI P
暴露组 非暴露组 P I2(%)
再次移植 血液 5 70/381 328/1 977 >0.1 25 1.16 0.87~ 1.56 0.320
? 尿液 2 84/176 282/726 ≤0.1 84 1.51 0.62~ 3.65 0.360
排斥反应 血液 13 232/1 067 367/2 966 ≤0.1 63 1.91 1.30~ 2.80 0.001
? 尿液 10 173/389 617/1 973 ≤0.1 70 1.46 0.85~ 2.50 0.170
移植肾功能延迟恢复 血液 8 95/416 318/2 019 ≤0.1 45 1.51 0.99~ 2.31 0.006
? 尿液 8 79/225 653/1 895 >0.1 8 0.96 0.71~ 1.30 0.780
他克莫司vs环孢素 血液 14 413/2 045 201/1 382 >0.1 9 1.50 1.22~ 1.84 <0.000
? 尿液 9 349/1 077 183/568 ≤0.1 59 1.46 0.93~ 2.29 0.100
糖皮质激素 血液 5 208/1 106 84/616 >0.1 22 1.26 0.86~ 1.84 0.230
? 尿液 3 141/306 182/526 >0.1 56 1.49 1.09~ 2.04 0.010
ATG vs无免疫诱导 血液 2 36/113 40/175 ≤0.1 66 1.75 1.02~ 2.98 0.040
ATG vs巴利昔单抗 血液 3 74/319 49/299 >0.1 0 1.04 0.64~ 1.69 0.860
? 尿液 3 154/320 115/299 >0.1 0 1.32 0.89~ 1.96 0.160
阿伦单抗vs巴利昔单抗 血液 2 108/438 15/81 >0.1 0 0.79 0.39~ 1.58 0.500
群体反应性抗体 血液 6 68/412 265/2 275 >0.1 0 1.35 0.99~ 1.84 0.060
? 尿液 3 68/156 122/294 >0.1 27 1.12 0.75~ 1.68 0.590
吗替麦考酚酯 血液 4 204/1 162 19/330 ≤0.1 87 2.24 0.48~10.41 0.300
? 尿液 2 119/372 5/18 >0.1 0 1.23 0.42~ 3.60 0.710
输尿管支架 血液 2 100/428 21/161 >0.1 18 1.98 1.19~ 3.30 0.009
CMV 血液 4 78/362 158/1 400 >0.1 42 2.23 1.61~ 3.09 <0.000
? 尿液 2 32/70 237/643 >0.1 0 1.44 0.88~ 2.37 0.150
1
Gardner SD, Field AM, Coleman DA. New human papovavirus(BK) isolated from urine after renal transplantation[J]. Lancet, 1971, 1(7712):1253-1257.
2
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients[J]. N Engl J Med, 2002, 347(7):488-496.
3
Vigil D, Konstantinov NK, Barry M, et al. BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection[J]. World J Transplant, 2016, 6(3):472-504.
4
Costa C, Cavallo R. Polyomavirus-associated nephropathy[J]. World J Transplant, 2012, 2(6): 84-94.
5
Borni-Duval C, Caillard S, Olagne J, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring[J]. Transplantation, 2013, 95(12):1498-1505.
6
Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication[J]. Transplantation, 2008, 86(4):521-528.
7
Huang G, Zhang L, Liang X, et al. Risk factors for BK virus infection and BK virus-associated nephropathy under the impact of intensive monitoring and pre-emptive immunosuppression reduction[J]. Transplant Proc, 2014, 46(10):3448-3454.
8
Masutani K, Ninomiya T, Randhawa P, et al. HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia[J]. Nephrol Dial Transplant, 2013, 28(12):3119-3126.
9
Moura EB, Petzhold SV, Amaral AR, et al. Evaluation of the predisposition and clinical impact of BK virus replication in kidney transplant patients[J]. An Acad Bras Cienc, 2017, 89(1 Suppl 0):675-684.
10
Radtke J, Dietze N, Fischer L, et al. Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy[J]. Transpl Infect Dis, 2016, 18(6):850-855.
11
Saundh BK, Baker R, Harris M, et al. Early BK polyomavirus (BKV) reactivation in donor kidney is a risk factor for development of BKV-associated nephropathy[J]. Infect Dis, 2013, 207(1):137-141.
12
Schachtner T, Babel N, Reinke P. Different risk factor profiles distinguish early-onset from late-onset BKV-replication[J]. Transpl Int, 2015, 28(9):1081-1091.
13
Shenagari M, Monfared A, Eghtedari H, et al. BK virus replication in renal transplant recipients: Analysis of potential risk factors may contribute in reactivation[J]. Clin Virol, 2017, 96:7-11.
14
Siparsky NF, Kushnir LF, Gallichio MH, et al. Ureteral stents: a risk factor for polyomavirus BK viremia in kidney transplant recipients undergoing protocol screening[J]. Transplant Proc, 2011, 43(7):2641-2644.
15
Steubl D, Baumann M, Schuster T, et al. Risk factors and interventional strategies for BK polyomavirus infection after renal transplantation[J]. Scand J Urol Nephrol, 2012, 46(6):466-474.
16
Theodoropoulos N, Wang E, Penugonda S, et al. BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation[J]. Am J Transplant, 2013, 13(1):197-206.
17
Vu D, Sakharkar P, Shah T, et al. Association of interferon gamma gene polymorphisms with BK virus infection among Hispanic renal allograft recipients[J]. Transplantation, 2014, 97(6):660-667.
18
Wingate JT, Brandenberger J, Weiss A, et al. Ureteral stent duration and the risk of BK polyomavirus viremia or bacteriuria after kidney transplantation[J]. Transpl Infect Dis, 2017, 19(1).
19
Wunderink HF, van der Meijden E, van der Blij-de Brouwer CS, et al. Pretransplantation donor-recipient pair seroreactivity against BK polyomavirus predicts viremia and nephropathy after kidney transplantation[J]. Am J Transplant, 2017, 17(1):161-172.
20
龙建华,谢娟娟,钱坤,等. DCD供肾肾移植术后BK病毒感染情况及危险因素分析[J]. 中国社区医师,2018, 34(27):34-35.
21
张磊,田野. 肾移植后受者BK病毒血症的高危因素分析[J]. 中国组织工程研究与临床康复,2009, 13(31):6023-6026.
22
屠国伟,朱同玉,唐群业,等. 肾移植患者BK病毒感染的诊断和危险因素分析[J]. 复旦学报(医学版), 2009, 36(5):557-561.
23
陆明,朱有华,王皓,等. 肾移植患者术后BK病毒感染的检测及危险因素分析[J]. 第二军医大学学报,2007, 28(1):71-76.
24
刘路鹏. 肾移植受者BK病毒的检测及感染危险因素分析[D]. 北京:中国人民解放军军医进修学院,2009.
25
费爽,黄正楷,周万里,等. 肾移植受者BK病毒感染及其危险因素的单中心研究[J]. 南京医科大学学报(自然科学版), 2017, 37(5):588-592.
26
李平,程东瑞,季曙明,等. 肾移植术后BK病毒感染及危险因素分析[J]. 医学研究生学报,2017, 30(5):525-529.
27
Harza M, Tacu D, Mitroi G, et al. Polyomavirus BK-associated nephropathy after kidney transplantation: a single-center retrospective analysis[J]. Rom J Morphol Embryol, 2014, 55(1):123-128.
28
Abend JR, Changala M, Sathe A, et al. Correlation of BK virus neutralizing serostatus with the incidence of BK viremia in kidney transplant recipients[J]. Transplantation, 2017, 101(6):1495-1505.
29
明英姿,魏伟,刘洪,等. 肾移植与BK病毒感染[J]. 器官移植,2016, 7(6):427-432.
[1] 明昊, 肖迎聪, 巨艳, 宋宏萍. 乳腺癌风险预测模型的研究现状[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 287-291.
[2] 庄燕, 戴林峰, 张海东, 陈秋华, 聂清芳. 脓毒症患者早期生存影响因素及Cox 风险预测模型构建[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 372-378.
[3] 蒋敏, 刘馨竹, 李大伟, 冯柏塨, 申传安. 点阵CO2激光联合其他非手术方式治疗痤疮瘢痕有效性的网状荟萃分析[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 429-439.
[4] 黄鸿初, 黄美容, 温丽红. 血液系统恶性肿瘤患者化疗后粒细胞缺乏感染的危险因素和风险预测模型[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 285-292.
[5] 罗文斌, 韩玮. 胰腺癌患者首次化疗后中重度骨髓抑制的相关危险因素分析及预测模型构建[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 357-362.
[6] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[7] 中华医学会器官移植学分会. 遗体捐献肾脏获取手术技术操作指南[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 257-265.
[8] 邹永康, 石雍, 徐贤刚, 张帅民, 刘衍, 杨生鹏, 叶啟发, 陈根, 张毅. 肾移植术后手术切口米根霉感染伴菌血症一例并文献复习[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 289-292.
[9] 林凯, 潘勇, 赵高平, 杨春. 造口还纳术后切口疝的危险因素分析与预防策略[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 634-638.
[10] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[11] 孙昭, 刘琪, 王殿琛, 姜建武, 符洋. 机器人对比腹腔镜及开放式腹股沟疝修补术的Meta 分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 588-598.
[12] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[13] 司楠, 孙洪涛. 创伤性脑损伤后肾功能障碍危险因素的研究进展[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(05): 300-305.
[14] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
[15] 李文哲, 王毅, 崔建, 郑启航, 王靖彦, 于湘友. 新疆维吾尔自治区重症患者急性肾功能异常的危险因素分析[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 269-276.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?